Trial Profile
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms Portal
- Sponsors Roche
- 11 Feb 2022 According to a Genentech media release, data will be presented at Angiogenesis, Exudation and Degeneration 2022.
- 30 Nov 2021 Planned End Date changed from 31 Jul 2026 to 31 Dec 2026.
- 30 Nov 2021 Planned primary completion date changed from 31 Jul 2026 to 31 Dec 2026.